Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930.

[1]  D. Ribatti.  Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. , 2011, Cancer treatment reviews.

[2]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[3]  S. Bates,et al.  Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. , 2009, Biochemical pharmacology.

[4]  Deborah Ferriola,et al.  Tyrosine kinase blockers: new hope for successful cancer therapy. , 2009, Anti-cancer agents in medicinal chemistry.

[5]  N. Azizi,et al.  Highly chemoselective reductive amination-coupling by one-pot reaction of aldehydes, HMDS and NaBH4 , 2008 .

[6]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[7]  S. Deacon,et al.  The challenge of selecting protein kinase assays for lead discovery optimization , 2008, Expert opinion on drug discovery.

[8]  R. Prasad,et al.  Reductive amination of carbonyl compounds using NaBH4 in a Brønsted acidic ionic liquid , 2007 .

[9]  J. P. Bowen,et al.  Molecular design and clinical development of VEGFR kinase inhibitors. , 2007, Current topics in medicinal chemistry.

[10]  Janet Morgan,et al.  The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2 , 2007, Clinical Cancer Research.

[11]  R. Roskoski.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[12]  A. Panfilov,et al.  Reactions of Sodium Borohydride in Acetic Acid: Reductive Amination of Carbonyl Compounds , 2004, Pharmaceutical Chemistry Journal.

[13]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[14]  D. Channe Gowda,et al.  Hydrazinium Monoformate: A New Hydrogen Donor. Selective Reduction of Nitrocompounds Catalyzed by Commercial Zinc Dust , 2003 .

[15]  P. Portoghese,et al.  Electrophilic N-benzylnaltrindoles as delta opioid receptor-selective antagonists. , 1995, Journal of medicinal chemistry.

[16]  W. L. Nelson,et al.  Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol. , 1995, Journal of medicinal chemistry.

[17]  J. Coe,et al.  A mild method for the conversion of activated aryl methyl groups to carboxaldehydes via the uncatalyzed periodate cleavage of enamines , 1994 .

[18]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[19]  O. W. Rees,et al.  THE REDUCTION OF AROMATIC NITRO COMPOUNDS TO AMINES WITH HYDROGEN AND PLATINUM-OXIDE PLATINUM BLACK AS A CATALYST. XIV1 , 1927 .